In addition, various neuronal cell populations are responsive to multiple neurotrophic factors. 2 This abundance of riches can make it difficult to decide how best to investigate the therapeutic potential of the different neurotrophic factors.
Hypothetically, the ideal cocktail of molecules could help nourish back to health all sorts of ailing neurons, ranging from peripheral motor and sensory nerves, to ascending and descending spinal pathways, to brain stem monoamine neurons, to cortical cholinoceptive neurons. Even cells in specialized sense organs such as the vestibular system, cochlea, and retina appear to be responsive to various neurotrophic factors.
No Thanks, We're Psychiatrists
Almost all of the research on neurotrophic factors has been conducted in animals, and most of the research targets are neurons involved in neurologic illnesses such as amyotrophic lateral sclerosis, various peripheral neuropathies, spinal cord trauma, Parkinson's disease, and Alzheimer's disease. [2] [3] [4] [5] The long-term therapeutic potential of neurotrophic factors should, nevertheless, be of interest to psychiatrists as well, because there are hints that such molecules could regulate functions of neurons likely to be involved in the progressive course of schizophrenia, "kindling" in bipolar illness, and the development of treatment resistance in depression, panic, and various other disorders. 2, 6 Although such clinical applications are a long way off, new understanding about how neurons survive and innervate their targets of communication is evolving at an everquickening pace. Applying knowledge of the actions of neurotrophic factors and recognition molecules that help guide sprouting axons 7, 8 might someday increase the odds that dysfunctional neurons in the mature nervous system will be salvaged, or even that desirable synaptic connections could be facilitated. Many more studies are planned, and a great many neurotrophic factors and chemically modified analogues are being developed. Someday it may be possible for neurotrophic factors to get on our nerves. x
You Can't Get There From Here
There are numerous problems in using neurotrophic factors as therapeutics. Such a large quantity of neurons are responsive to them that systemic administration may well activate all kinds of axonal sprouts that are not desired. Perhaps high doses or chronic use could be mitogenic, increasing the risk of cancer. When neurotrophic factors have been administered experimentally to both animals and humans, some unexpected consequences have been observed including appetite suppression, weight loss, increased pain perception, and muscle aches. 2 Thus, localized administration to the desired site of action, or site-selective actions of systemically administered neurotrophic factors, may be required if treatment is going to be safe.
To complicate application of this research, growth factors are large protein or peptide molecules unable to survive intact when orally administered and unable to cross the bloodbrain barrier when administered intravenously. This has led to at least 5 approaches to delivering neurotrophic factors to their desired targets in the central nervous system. First, the protein itself can be infused directly into the cerebrospinal fluid or implanted in a biodegradable, slow-release preparation. Second, the active protein can get a trip across the blood-brain barrier by hiding inside a "Trojan horse" molecule that is normally translocated across the barrier. Third, chemists might be able to make low molecular weight versions of trophic factors that can pass the blood-brain barrier. Fourth, a low molecular weight drug may be able to get into the brain and pharmacologically induce the formation of a trophic factor. This action, in fact, has been suggested for cholinesterase inhibitors, which not only increase acetylcholine levels, but subsequently increase nerve growth factor. Finally, a high-tech idea is to transfer genes that produce the trophic factor directly into the brain by grafting cells that normally make it, by genetically engineering them to make it, or by delivering the gene in a carrier virus. All of these possibilities are under active investigation.
Ongoing Clinical Investigations
Some neurotrophic factors have actually been tested in man. Chemotherapy-induced peripheral neuropathy has been tested with a synthetic neurotrophic analogue and has shown promising results. 2 Nerve growth factor (NGF) is in early testing in diabetic neuropathy.
2 Ciliary neurotrophic factor (CNTF) has been studied in amyotrophic lateral sclerosis but failed to demonstrate efficacy and fully developed neuron degenerated neuron neurotrophic growth factor
